Education
About Us
Working with TipRanks
Follow Us
ProQR (PRQR)
NASDAQ:PRQR
PRQR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.59 - $4.62
Previous CloseN/A
Volume75.97K
Average Volume (3M)482.96K
Market Cap
$173.60M
Enterprise Value$66.50M
Total Cash (Recent Filing)€149.41M
Total Debt (Recent Filing)€17.22M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
May 08, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding105,212,524
10 Day Avg. Volume754,452
30 Day Avg. Volume482,960
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.70
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.67Price Target Upside546.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
ProQR News
---
Bulls Say, Bears Say
Bulls Say
Financial PositionPRQR ended with $156M in cash, which management estimates is sufficient runway into mid-2027.
Market OpportunityPRQR's RNA editing therapy, targeting the bile acid transporter for cholestatic diseases, addresses a multi-billion-dollar market, presenting a substantial long-term opportunity.
PartnershipsPartnership with Eli Lilly underscores platform value and opens the door for milestone payments down the road.
Bears Say
Pipeline ChallengesCatalysts are expected to return after a multi-year pipeline reset following the LCA10 failure, with key developments anticipated in the coming years.
Stock PerformanceThe continued stock decline following a mid-October spike suggests recent market challenges for PRQR.
---
Ownership Overview
―
Insiders
2.60% Mutual Funds
32.46% Other Institutional Investors
64.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.59 and its highest was $4.62 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $173.60M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is May 08, 2025 which is in 44 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Mar 13, 2025. The company reported -$0.097 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.003.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.1.
How many shares outstanding does ProQR have?
ProQR has 105,212,524 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.097 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went down -5.946%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in PRQR
---
ProQR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (546.67% Upside)
$10.67 (546.67% Upside)
Hedge Fund Trend
Increased
By 5.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.67%
12-Months-Change
Fundamentals
Return on Equity
-43.72%
Trailing 12-Months
Asset Growth
14.19%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
---
PRQR Stock 12 Month Forecast
Average Price Target
$10.67
▲(546.67% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
PTC Therapeutics
―
RegenXBio
―
Editas Medicine
―
Best Analysts Covering PRQR
1 Year
1 Year Success Rate
11/26 ratings generated profit
1 Year Average Return
-12.35%
reiterated a buy rating 13 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 42.31% of your transactions generating a profit, with an average return of -12.35% per trade.
---